Aquestive Therapeutics Inc. 在其 Anaphylm™（肾上腺素）舌下薄膜的全球扩张战略中迈出重要一步。公司已获得与加拿大卫生部的会晤机会，定于 2025 年第三季度举行，届时将深入讨论在加拿大的新药提交计划。与此同时，Aquestive 向欧洲药品管理局递交了初步简报文件，并即将提交正式的市场授权申请。此举彰显公司雄心：将 Anaphylm™ 打造为全球治疗严重过敏反应和过敏性休克的新标准疗法。依托其深厚的监管经验与商业化专长——旗下六种 FDA 批准药物覆盖六大洲——Aquestive 致力于突破治疗壁垒。Anaphylm™ 的口服给药方式巧妙化解了针恐惧症和设备故障等核心难题。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.